Finding studies
Finding studies
Take this into the appointment.
Saves the questions and what to expect into your notes, next to the visit they belong to.
Lead
Kanyos Bio, Inc., a wholly-owned subsidiary of Anokion SA
Study KAN-101-01 is a Phase 1, FIH study designed to evaluate the safety and tolerability of KAN-101 in patients with celiac disease on a gluten free diet (GFD). An overview of the two parts and proposed dose groups is given below: 1. Part A (SAD): Patients will receive a single dose of KAN-101. 2. Part B (MAD): Patients will receive three doses of either KAN-101 or placebo.
Age
18–70
Sex
ALL
Healthy volunteers
Not accepted